Hansa Biopharma AB (publ)
SSE:HNSA.ST
32.64 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Hansa Biopharma AB (publ) |
Symbool | HNSA.ST |
Munteenheid | SEK |
Prijs | 32.64 |
Beurswaarde | 1,719,207,552 |
Dividendpercentage | 0% |
52-weken bereik | 20.14 - 58.1 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Søren Tulstrup M.Sc |
Website | https://www.hansabiopharma.com |
An error occurred while fetching data.
Over Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)